first proof of principle for EpiSwitch™ biomarkers in non-invasive diagnosis of canine lymphoma

OBD presents results of a study at the AACR Conference on Advances in Liquid Biopsies, demonstrating the utility of EpiSwitch™ biomarkers for the diagnosis of canine lymphoma which accounts for 84% of blood cell malignancies and 24% of all tumours in dogs.

https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/OBD/14385527.html